Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Cnpharm Co. Ltd. is navigating 3 pending office actions within the Chemistry & Materials technology area. These actions are spread across 2 distinct art units, showing some technical concentration in the USPTO. The prosecution involves 3 distinct examiners, which means every pending action is being reviewed by a different individual. This distribution requires the applicant to manage separate examiner relationships simultaneously. The presence of 2 distinct art units indicates that the pending office actions are being evaluated under slightly different departmental guidelines.
YOUNGBLOOD, WILLIAM JUSTIN is the busiest examiner for this portfolio, with 1 pending office action under review. Since there are distinct examiners for the pending actions, no examiner holds the bulk of the workload. This distribution requires a strategy that accounts for the varied perspectives of the examiners. Managing these pending office actions across the distinct art units suggests that the Chemistry & Materials filings are somewhat specialized. The applicant must ensure that arguments presented to YOUNGBLOOD, WILLIAM JUSTIN remain consistent with those provided to the other examiners involved in the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.7% |
| KAUCHER, MARK S | 1 | 72.4% | +14.0% |
| KIM, DANIELLE A | 1 | 37.1% | +56.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18844613 | PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PREPARATION METHOD THEREFOR | YOUNGBLOOD, WILLIAM JUSTIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17428111 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KIM, DANIELLE A | 53d overdue |
| 18844613 | PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PREPARATION METHOD THEREFOR | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18587826 | NOVEL CATIONIC POLYPHOSPHAZENE COMPOUND, POLYPHOSPHAZENES-DRUG CONJUGATE COMPOUND AND METHOD FOR PREPARING SAME | KAUCHER, MARK S | — |
| Art Unit | Apps |
|---|---|
| 1764 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844613 | PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PREPARATION METHOD THEREFOR | YOUNGBLOOD, WILLIAM JUSTIN | — | §102§112 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18587826 | NOVEL CATIONIC POLYPHOSPHAZENE COMPOUND, POLYPHOSPHAZENES-DRUG CONJUGATE COMPOUND AND METHOD FOR PREPARING SAME | KAUCHER, MARK S | 1764 | §112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 17428111 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KIM, DANIELLE A | 1613 | §103 | Final Rejection | 53d overdue | Pending | Aug 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial